JP2018522867A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522867A5
JP2018522867A5 JP2017567218A JP2017567218A JP2018522867A5 JP 2018522867 A5 JP2018522867 A5 JP 2018522867A5 JP 2017567218 A JP2017567218 A JP 2017567218A JP 2017567218 A JP2017567218 A JP 2017567218A JP 2018522867 A5 JP2018522867 A5 JP 2018522867A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
hydrate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017567218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522867A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/039302 external-priority patent/WO2016210291A1/en
Publication of JP2018522867A publication Critical patent/JP2018522867A/ja
Publication of JP2018522867A5 publication Critical patent/JP2018522867A5/ja
Pending legal-status Critical Current

Links

JP2017567218A 2015-06-26 2016-06-24 縮合二環式ピリミジン誘導体およびこれらの使用 Pending JP2018522867A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185366P 2015-06-26 2015-06-26
US62/185,366 2015-06-26
PCT/US2016/039302 WO2016210291A1 (en) 2015-06-26 2016-06-24 Fused bicyclic pyrimidine derivatives and uses thereof

Publications (2)

Publication Number Publication Date
JP2018522867A JP2018522867A (ja) 2018-08-16
JP2018522867A5 true JP2018522867A5 (enExample) 2019-07-25

Family

ID=57585794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567218A Pending JP2018522867A (ja) 2015-06-26 2016-06-24 縮合二環式ピリミジン誘導体およびこれらの使用

Country Status (7)

Country Link
US (1) US10342798B2 (enExample)
EP (1) EP3313529A4 (enExample)
JP (1) JP2018522867A (enExample)
AU (1) AU2016283100A1 (enExample)
CA (1) CA2988461A1 (enExample)
HK (1) HK1254469A1 (enExample)
WO (1) WO2016210291A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
JP6947651B2 (ja) 2015-06-26 2021-10-13 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 4,6−ピリミジニレン誘導体およびこれらの使用
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
CN107557370B (zh) * 2017-09-25 2020-03-17 华南农业大学 水稻rel1基因在提高植物抗干旱胁迫中的应用
CN111936484A (zh) * 2017-12-22 2020-11-13 拉文纳制药公司 作为磷脂酰肌醇磷酸激酶抑制剂的色烯并吡啶衍生物
WO2019126733A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド Taireファミリーキナーゼインヒビターおよびそれらの使用
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CN109879887B (zh) * 2019-04-16 2021-07-20 辽宁大学 含吲哚结构的噻吩并[3,2-d]嘧啶类衍生物及其应用
CN114133394B (zh) * 2020-08-12 2023-12-08 赛诺哈勃药业(成都)有限公司 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途
EP4259128A4 (en) * 2020-12-09 2025-04-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2022246025A1 (en) * 2021-05-20 2022-11-24 Dana-Farber Cancer Institute, Inc. Inhibitors and degraders of pip4k protein
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023227125A1 (zh) * 2022-05-26 2023-11-30 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2023246371A1 (zh) * 2022-06-24 2023-12-28 中国科学院基础医学与肿瘤研究所(筹) 具有嘧啶并噻吩结构的小分子化合物及其应用
CN119874680A (zh) * 2025-03-27 2025-04-25 浙大城市学院 含2-氯丙烯酰胺的2-氨基嘧啶类化合物、其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305435T3 (es) * 2002-01-10 2008-11-01 Bayer Healthcare Ag Inhibidores de la rho-quinasa.
AU2010343102B2 (en) * 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP6106685B2 (ja) * 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド C−jun−n−末端キナーゼ(jnk)の阻害剤
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
US10112927B2 (en) * 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN103242341B (zh) 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2,4取代嘧啶类化合物及其药物组合物与应用
CN104177363B (zh) * 2013-05-24 2018-06-05 江苏先声药业有限公司 双环杂环胺类Hedgehog信号通路抑制剂
EP3057956B1 (en) * 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2018522867A5 (enExample)
JP2018522866A5 (enExample)
JP2019527682A5 (enExample)
JP2018515434A5 (enExample)
JP2019524883A5 (enExample)
JP2017537940A5 (enExample)
JP2014510774A5 (enExample)
CN102971312B (zh) 吡咯取代的2-二氢吲哚酮衍生物、其制备方法及用途
ES2594378T3 (es) Derivados de la bencilidenoguanidina y uso terapéutico para el tratamiento de enfermedades por mal plegamiento proteico
JP2013500304A (ja) 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール
JP2017502006A5 (enExample)
JP2017524733A5 (enExample)
JP2014508804A5 (enExample)
JP2018531987A5 (enExample)
EP3154982A1 (en) Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
JP2013516480A5 (enExample)
JP2016525104A5 (enExample)
JP2020516616A5 (enExample)
CN102241674A (zh) 1,1-二甲基-β-咔啉-3-甲酰基氨基酸苄酯的合成和抗肿瘤活性评价
JP2019521964A5 (enExample)
US11883423B2 (en) Nucleobase analogue derivatives and their applications
CN112321568B (zh) 4-甲基吡咯取代的吲哚酮衍生物、其制备方法及其医药用途
JPWO2021133896A5 (enExample)
JP2008519815A5 (enExample)
AU2020226633A1 (en) Nurr1 receptor modulators